愛博醫療(688050.SH)業績快報：2020年度淨利升44.80%至9655.83萬元
格隆匯 2 月 23日丨愛博醫療(688050.SH)披露2020年度業績快報，實現營業總收入2.73億元，同比增長39.88%；歸屬於母公司所有者的淨利潤9655.83萬元，同比增長44.80%；歸屬於母公司所有者的扣除非經常性損益的淨利潤8967.92萬元，同比增長41.22%；基本每股收益1.08元。
2020年第一季度受新冠疫情及春節假期影響，終端醫療機構的白內障手術和角膜塑形鏡驗配業務大幅減少，公司營業收入和歸屬於母公司所有者的淨利潤同比大幅下降。第二季度隨着國內疫情好轉，市場逐漸恢復，公司營業收入和歸屬於母公司所有者的淨利潤恢復快速增長。第三季度、第四季度公司營業收入和歸屬於母公司所有者的淨利潤持續保持着較高的增長速度，在人工晶狀體業務穩定增長的同時，角膜塑形鏡業務隨着公司加強市場推廣，品牌影響逐步提升，銷量快速增長，角膜塑形鏡(含試戴片)全年銷量突破10萬片。
報吿期內，研發投入總額3992.02萬元，同比增長39.28%。公司克服疫情困難，持續加大研發投入，有效保障了公司研發進度。其中：預裝式非球面人工晶狀體A1UL22、A1UL24、A1UL28於2020年5月19日經國家藥品監督管理局批准取得《醫療器械註冊證》(國械注準20203160517)；非球面衍射型多焦人工晶狀體(已通過國家藥品監督管理局醫療器械技術審評中心創新醫療器械特別審查程序)、多功能硬性接觸鏡護理液等護理產品已完成臨牀隨訪，準備申報註冊；有晶體眼人工晶狀體、眼用透明質酸鈉凝膠正在穩步推進臨牀試驗。
報吿期內，公司營業總收入同比增長39.88%，其中：人工晶狀體同比增長24.70%，角膜塑形鏡同比增長479.59%。公司人工晶狀體自產品上市以來憑藉先進的技術、高效的服務及不斷推出的新產品，一直保持着快速增長。除2020年第一季度受疫情影響致使人工晶狀體銷量、收入同比大幅下降40%以上外，第二、三、四季度人工晶狀體銷量、收入同比增長均在30%以上，其中人工晶狀體帶量採購政策促進了公司終端客户數量的持續增加。角膜塑形鏡行業市場總量整體處於上升時期，公司憑藉獨特的產品設計、多樣化的市場推廣，角膜塑形鏡(含試戴片)全年銷量突破10萬片，實現營業收入4126.04萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
